about
Osteoimmunology: interactions of the bone and immune systemThe HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replicationAdenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinomaAdenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model.HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.Multifunctional CD40L: pro- and anti-neoplastic activity.Expression and purification of soluble murine CD40L monomers and polymers in yeast Pichia pastoris.A functional TNFRSF5 gene variant is associated with risk of lymphomaDesign and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patientsAdvanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.MicroRNA profiling of CD3+ CD56+ cytokine-induced killer cells.AdCD40L--crossing the valley of death?Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
P2860
Q24655113-3EEA5DC1-7568-4720-BB6A-1CCBFA408C92Q28477188-E54C88C3-157F-41CD-BD2E-DA68337CBE9BQ28572729-FFB4104A-3EAB-46ED-93DD-CC4285F671A3Q33587584-11FD6141-5F9C-400B-B07C-C35C3522031EQ33975595-14DFB390-8D99-43BF-B2F1-6127C0DB5D68Q34238526-51B5CD87-7767-4AC6-BB60-4E727F110C91Q34422566-6D40C629-4378-4DAC-9FFE-D93EF971345AQ34423954-F1C655B6-4F26-41A5-811D-7C6EC7AF3211Q36528811-83430E8C-B466-49B3-8150-848373E70BA3Q36777133-2A8417DB-DDBA-4CC9-BBE8-6A275BF8A0EAQ37174695-034F0355-D889-44A1-BF9D-9557EFF28822Q37629088-9E9CDF91-03DE-4331-901E-4DEF068FDD65Q37659577-4C4F9BD3-9ABF-4CF1-ABAA-37C422B5968FQ37737350-A8198D38-D049-42FA-BF00-2D65FC8A6B37Q38026926-1B4F6755-AE5C-4C83-AAD5-A7D6190014CEQ38054112-DE85F3D5-6E9A-4244-A7FE-6AF9866ACE96Q39311520-8A8D90D9-31B4-4E12-B35E-DD80B5FC4ADCQ39974466-F438BC37-D145-4E6F-903B-BD132B5C0F9D
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CD40L - a multipotent molecule for tumor therapy.
@ast
CD40L - a multipotent molecule for tumor therapy.
@en
type
label
CD40L - a multipotent molecule for tumor therapy.
@ast
CD40L - a multipotent molecule for tumor therapy.
@en
prefLabel
CD40L - a multipotent molecule for tumor therapy.
@ast
CD40L - a multipotent molecule for tumor therapy.
@en
P1476
CD40L - a multipotent molecule for tumor therapy
@en
P2093
Thomas H Tötterman
P356
10.2174/187153007780059432
P577
2007-03-01T00:00:00Z